Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)

 
ZYNE Technical Analysis
5
As on 18th May 2022 ZYNE Share Price closed @ 0.92 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.47 & Strong Sell for SHORT-TERM with Stoploss of 4.15 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ZYNE Share Price

Open 1.00 Change Price %
High 1.04 1 Day -0.07 -7.07
Low 0.90 1 Week -0.22 -19.30
Close 0.92 1 Month -1.11 -54.68
Volume 273280 1 Year -3.57 -79.51
52 Week High 8.76 | 52 Week Low 0.86
 
NASDAQ USA Most Active Stocks
AMD 96.28 -6.04%
AAPL 140.82 -5.64%
BRQS 0.19 11.76%
SNDL 0.41 -6.82%
GNUS 0.78 13.04%
AGRI 2.92 8.96%
BBIG 3.05 6.64%
ENDP 0.62 -46.55%
NVDA 169.38 -6.82%
SOFI 7.23 2.55%
 
NASDAQ USA Top Gainers Stocks
NDRAW 0.03 200.00%
EYESW 0.48 92.00%
SMIHW 0.15 87.50%
ZJZZT 38.00 78.82%
THCAW 0.33 73.68%
WKSPW 0.63 57.50%
TMPMW 0.11 57.14%
BROGW 0.42 55.56%
PPHPR 0.14 55.56%
EFTRW 0.23 53.33%
 
NASDAQ USA Top Losers Stocks
PTRAW 0.23 -89.59%
VENAW 0.05 -50.00%
ALACW 0.01 -50.00%
BTAQW 0.01 -50.00%
ENDP 0.62 -46.55%
MDGSW 0.21 -44.74%
ALACR 0.04 -42.86%
IKNX 19.52 -42.42%
NLITW 0.09 -40.00%
ROVRW 1.30 -34.34%
 
 
ZYNE
Daily Charts		 ZYNE
Intraday Charts		 Whats New @
Bazaartrend		 ZYNE
Free Analysis
 
ZYNE Important Levels Intraday
RESISTANCE1.19
RESISTANCE1.10
RESISTANCE1.05
RESISTANCE1.00
SUPPORT0.84
SUPPORT0.79
SUPPORT0.74
SUPPORT0.65
 
ZYNE Target for Month May
Share
4th UP TARGET6.8
3rd UP TARGET4.91
2nd UP TARGET3.75
1st UP TARGET2.58
1st DOWN TARGET-0.74
2nd DOWN TARGET-1.91
3rd DOWN TARGET-3.07
4th DOWN TARGET-4.96
 
ZYNE Weekly Target
4th UP TARGET2.52
3rd UP TARGET2.01
2nd UP TARGET1.69
1st UP TARGET1.37
1st DOWN TARGET0.47
2nd DOWN TARGET0.15
3rd DOWN TARGET-0.17
4th DOWN TARGET-0.68
 
ZYNE Target for Year 2022
4th UP TARGET16.64
3rd UP TARGET11.6
2nd UP TARGET8.48
1st UP TARGET5.37
1st DOWN TARGET-3.53
2nd DOWN TARGET-6.64
3rd DOWN TARGET-9.76
4th DOWN TARGET-14.8
 
 
ZYNE Other Details
Segment EQ
Market Capital 155518160.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
ZYNE Address
ZYNE
 
ZYNE Latest News
 
Your Comments and Response on Zynerba Pharmaceuticals Inc
 
ZYNE Business Profile
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Address: 80 West Lancaster Avenue, Devon, PA, United States, 19333
 
© 2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service